$CORT

$87.59▲ 129.41% YTD

8 SEC 13D/G filings tracked · Last updated Oct 27, 2026

Filing History

CORT - Corcept Therapeutics Incorporated - SEC Filing Update (27-OCT-2026) | ThinkSabio - Stocks Simplified

$87.59▲ 129.41%Oct 27, 2026 · ThinkSabio Blog

$CORT SEC 13D/G institutional ownership filing. Healthcare sector. SEC Filing Update: #CORT Corcept Therapeutics Incorporated : $87.59 Sector: Healthc…

News

CORT ▲ +0.3% - Corcept Therapeutics Incorporated

CP $87.59▲ +0.3%Oct 27, 2026 · ThinkSabio Blog

$CORT - Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call…

News

CORT ▼ -1.0% - Corcept Therapeutics Incorporated

CP $85.05▲ -1.0%Oct 26, 2026 · ThinkSabio Blog

$CORT - Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-…

News

CORT ▼ -1.0% - Corcept Therapeutics Incorporated

CP $85.05▲ -1.0%Oct 26, 2026 · ThinkSabio Blog

$CORT Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Re…

News

CORT ▼ -13.2% - Corcept Therapeutics Incorporated

CP $93.26▲ -13.2%Oct 23, 2026 · ThinkSabio Blog

$CORT vol lows following GMAB headlines…

News

CORT ▲ +3.9% - Corcept Therapeutics Incorporated

CP $116.45▲ +3.9%Oct 20, 2026 · ThinkSabio Blog

$CORT - 2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes…

News

CORT ▲ +0.0% - Corcept Therapeutics Incorporated

CP $117.50▲ +0.0%Sep 23, 2026 · ThinkSabio Blog

$CORT - Corcept Announces Planned Leadership Transition…

News

CORT ▼ -0.1% - Corcept Therapeutics Incorporated

CP $114.86▲ -0.1%Sep 18, 2026 · ThinkSabio Blog

$CORT - Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)…